Adam Kadlec

Director Ejecutivo en Rivermark Medical, Inc. .

Finance

Consumer Services

Health Technology

Perfil

Adam Kadlec is currently the President, Chief Executive Officer & Director at Rivermark Medical, Inc. and an Advisor at Golden Angels Investors LLC since 2018.
He completed his undergraduate and graduate degrees at the University of Wisconsin.

Cargos activos de Adam Kadlec

Empresas	Cargo	Inicio
Golden Angels Investors LLC Golden Angels Investors LLC Investment ManagersFinance Golden Angels Investors LLC (Golden Angels Investors) is a venture capital firm founded in 2002 by Timothy J Keane. The firm is headquartered in Brookfield, Wisconsin.	Consultor / Asesor	01/04/2018
Rivermark Medical, Inc. Rivermark Medical, Inc. Medical SpecialtiesHealth Technology The American company was founded by a practicing urologist with the aim of developing the preferred first-line device therapy for benign prostatic hyperplasia. The company's flagship product, the Flostent system, enables physicians to treat patients safely and efficiently, with minimal discomfort and reduced complications. Rivermark Medical plans to bring the Flostent system to market as their first product. The CEO of the company is Adam Kadlec.	Director Ejecutivo	01/08/2021

Todos los cargos activos de Adam Kadlec

Formación de Adam Kadlec.

University of Wisconsin

Graduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Adam Kadlec.

Relaciones

100 +

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Golden Angels Investors LLC Golden Angels Investors LLC Investment ManagersFinance Golden Angels Investors LLC (Golden Angels Investors) is a venture capital firm founded in 2002 by Timothy J Keane. The firm is headquartered in Brookfield, Wisconsin.	Finance
Rivermark Medical, Inc. Rivermark Medical, Inc. Medical SpecialtiesHealth Technology The American company was founded by a practicing urologist with the aim of developing the preferred first-line device therapy for benign prostatic hyperplasia. The company's flagship product, the Flostent system, enables physicians to treat patients safely and efficiently, with minimal discomfort and reduced complications. Rivermark Medical plans to bring the Flostent system to market as their first product. The CEO of the company is Adam Kadlec.	Health Technology